RT Conference Proceedings
T1 Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
A1 Shu, C. A.
A1 Goto, K.
A1 Ohe, Y.
A1 Besse, B.
A1 Park, K.
A1 Wang, Y.
A1 Griesinger, F.
A1 Yang, J. C-H.
A1 Felip, E.
A1 Sanborn, R. E.
A1 Caro, R. Bernabe
A1 Bauml, J. M.
A1 Chen, J.
A1 Fennema, E.
A1 Mahoney, J.
A1 Trani, L.
A1 Knoblauch, R. E.
A1 Thayu, M.
A1 Cho, B. C.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27229
UL https://hdl.handle.net/10668/27229
LA en
DS RISalud
RD Apr 6, 2025